These findings highlight that PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner and reinforce the potential of PLAG1 as a therapeutic target for sorafenib in the treatment of HCC. Here, GPX4 is linked to hepatocellular carcinoma.